Analysts Issue Forecasts for Omeros Co.’s FY2023 Earnings (NASDAQ:OMER)

Omeros Co. (NASDAQ:OMER – Get Rating) – Stock analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Omeros in a report released on Wednesday, March 15th. Cantor Fitzgerald analyst B. Folkes forecasts that the biopharmaceutical company will post earnings of ($2.61) per share for the year. The consensus estimate for Omeros’ current full-year earnings is ($2.31) per share.

Other equities research analysts have also recently issued reports about the company. StockNews.com began coverage on Omeros in a research note on Thursday. They issued a “sell” rating for the company. UBS Group cut Omeros from a “buy” rating to a “neutral” rating in a research note on Thursday, December 8th.

Omeros Trading Down 9.9 %

Shares of NASDAQ OMER opened at $3.54 on Friday. Omeros has a twelve month low of $1.74 and a twelve month high of $7.75. The company has a current ratio of 3.25, a quick ratio of 7.30 and a debt-to-equity ratio of 2.58. The stock has a fifty day simple moving average of $3.61 and a 200-day simple moving average of $3.28. The stock has a market capitalization of $222.42 million, a PE ratio of 4.72 and a beta of 1.02.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CI Private Wealth LLC purchased a new position in Omeros in the fourth quarter valued at $1,453,000. Virtu Financial LLC purchased a new position in Omeros in the fourth quarter valued at $79,000. Man Group plc boosted its holdings in Omeros by 185.7% in the fourth quarter. Man Group plc now owns 41,295 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 26,842 shares during the period. Ancora Advisors LLC lifted its holdings in Omeros by 121.7% during the 4th quarter. Ancora Advisors LLC now owns 324,017 shares of the biopharmaceutical company’s stock worth $732,000 after buying an additional 177,870 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Omeros by 73.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 30,600 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 13,000 shares during the last quarter. 32.64% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

(Get Rating)

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.